Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Pneumococcal Vaccination in HIV Infected Individuals
NCT02515240Phase 1Completed
- Sponsor
- University of Toledo Health Science Campus
- Start
- Jul 2010
- Primary completion
- Jun 2014
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection (6 arms), sponsored by University of Toledo Health Science Campus. Primary endpoint: Antibody activity and response by opsonophagocytic assay (OPT) and ELISA at Day 30. Started Jul 2010; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02515240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515240.